Patent · US Expired

Production of recombinant adeno-associated virus vectors

US5354678A · kind A · utility

78Cited by
3References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 21, 1992
Grant dateOct 11, 1994
Priority date
Expiry dateDec 21, 2012

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Simplified methods to produce recombinant adeno-associated virus (rAAV) vectors are described. The methods involve the use of chimeric plasmids which incorporate the Epstein Barr nuclear antigen (EBNA) gene, the latent origin of replication of Epstein Barr virus (oriP), and a rAAV genome. The chimeric plasmids themselves are also a part of the present invention. These plasmids are maintained as multicopy extra-chromosomal elements in cells, such as human 293 cells. Permanent cell lines carrying these EBV/AAV plasmids are induced to produce large amounts of rAAV upon addition of wild-type, adeno-associated virus helper functions. Vectors produced in this manner are capable of transducing exogenous genes into other human cell lines and exhibit the attributes of vital elements produced by conventional methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.